Get it on Google Play

Polaryx receives FDA fast track designation for CLN2 treatment

March 17, 2026 8:30 AM EDT Send to a Friend
Polaryx Therapeutics Inc. (NASDAQ: PLYX) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to PLX-200 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login